Literature DB >> 9893050

FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer's patches by FTY720-induced lymphocyte homing.

Y Yanagawa1, Y Masubuchi, K Chiba.   

Abstract

FTY720, a novel immunosuppressant, sequesters circulating mature lymphocytes, especially T cells, within lymph nodes and Peyer's patches by accelerating lymphocyte homing, and thereby causes lymphocyte depletion in the blood. The FTY720-induced acceleration of lymphocyte homing appears to be mediated by lymphocyte homing receptors including CD62L, CD49d/beta7, and CD11a/CD18. In this study, expressions of CD62L, CD49d and CD11a on T cells in the peripheral blood, lymph nodes and Peyer's patches were analysed by flow cytometry in rats given FTY720 (1 mg/kg) orally. FTY720 markedly decreased the number of peripheral blood T cells, while not affecting CD62L, CD49d and CD11a expressions at 1-3 hr after administration. In contrast, both the frequency of CD62L-positive T cells and intensity of CD62L expression on T cells were increased in Peyer's patches but not lymph nodes at 3 hr after administration of FTY720. CD49d and CD11a expressions on T cells were unaffected by FTY720 in both Peyer's patches and lymph nodes at the same point in time. On the other hand, analysis of lymphocyte homing with calcein-labelled lymphocytes and anti-CD62L monoclonal antibody (mAb) confirmed that FTY720 predominantly increased CD62L-dependent lymphocyte homing to Peyer's patches. These findings indicate that FTY720 increases the frequency of CD62L-positive T cells by accelerating CD62L-predominant homing in Peyer's patches.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9893050      PMCID: PMC1364357          DOI: 10.1046/j.1365-2567.1998.00639.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  21 in total

1.  An endothelial ligand for L-selectin is a novel mucin-like molecule.

Authors:  L A Lasky; M S Singer; D Dowbenko; Y Imai; W J Henzel; C Grimley; C Fennie; N Gillett; S R Watson; S D Rosen
Journal:  Cell       Date:  1992-06-12       Impact factor: 41.582

Review 2.  Overview of the mucosal immune system.

Authors:  P Brandtzaeg
Journal:  Curr Top Microbiol Immunol       Date:  1989       Impact factor: 4.291

3.  Inhibition of in vivo lymphocyte migration to inflammation and homing to lymphoid tissues by the TA-2 monoclonal antibody. A likely role for VLA-4 in vivo.

Authors:  T B Issekutz
Journal:  J Immunol       Date:  1991-12-15       Impact factor: 5.422

4.  Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1.

Authors:  C Berlin; E L Berg; M J Briskin; D P Andrew; P J Kilshaw; B Holzmann; I L Weissman; A Hamann; E C Butcher
Journal:  Cell       Date:  1993-07-16       Impact factor: 41.582

5.  Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in vivo.

Authors:  A Hamann; D P Andrew; D Jablonski-Westrich; B Holzmann; E C Butcher
Journal:  J Immunol       Date:  1994-04-01       Impact factor: 5.422

6.  Suppressor T cells for IgE and IgG in Peyer's patches of mice made tolerant by the oral administration of ovalbumin.

Authors:  J Ngan; L S Kind
Journal:  J Immunol       Date:  1978-03       Impact factor: 5.422

7.  Characterization of a CD3-like rat T cell surface antigen recognized by a monoclonal antibody.

Authors:  T Tanaka; T Masuko; H Yagita; T Tamura; Y Hashimoto
Journal:  J Immunol       Date:  1989-04-15       Impact factor: 5.422

Review 8.  The traffic of lymphocytes.

Authors:  W L Ford; J L Gowans
Journal:  Semin Hematol       Date:  1969-01       Impact factor: 3.851

9.  Characterization of the rat leukocyte integrin, CD11/CD18, by the use of LFA-1 subunit-specific monoclonal antibodies.

Authors:  T Tamatani; M Kotani; M Miyasaka
Journal:  Eur J Immunol       Date:  1991-03       Impact factor: 5.532

10.  In vivo administration of histoincompatible lymphocytes leads to rapid functional deletion of cytotoxic T lymphocyte precursors.

Authors:  D R Martin; R G Miller
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

View more
  22 in total

Review 1.  A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Authors:  Jerold Chun; Volker Brinkmann
Journal:  Discov Med       Date:  2011-09       Impact factor: 2.970

2.  Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury.

Authors:  Amandeep Bajwa; Sang-Kyung Jo; Hong Ye; Liping Huang; Krishna R Dondeti; Diane L Rosin; Volker H Haase; Timothy L Macdonald; Kevin R Lynch; Mark D Okusa
Journal:  J Am Soc Nephrol       Date:  2010-03-25       Impact factor: 10.121

3.  Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders.

Authors:  Jerold Chun; Yasuyuki Kihara; Deepa Jonnalagadda; Victoria A Blaho
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-01-06       Impact factor: 13.820

4.  Analysis of naïve lung CD4 T cells provides evidence of functional lung to lymph node migration.

Authors:  Stephane M Caucheteux; Parizad Torabi-Parizi; William E Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-14       Impact factor: 11.205

5.  Sphingosine 1-phosphate receptor-1 enhances mitochondrial function and reduces cisplatin-induced tubule injury.

Authors:  Amandeep Bajwa; Diane L Rosin; Piotr Chroscicki; Sangju Lee; Krishna Dondeti; Hong Ye; Gilbert R Kinsey; Brian K Stevens; Katarzyna Jobin; Brandon M Kenwood; Kyle L Hoehn; Kevin R Lynch; Mark D Okusa
Journal:  J Am Soc Nephrol       Date:  2014-08-21       Impact factor: 10.121

6.  Fingolimod modulates T cell phenotype and regulatory T cell plasticity in vivo.

Authors:  Margarita Dominguez-Villar; Khadir Raddassi; Ann Caroline Danielsen; Joseph Guarnaccia; David A Hafler
Journal:  J Autoimmun       Date:  2018-08-16       Impact factor: 7.094

Review 7.  Sphingosine kinase: Role in regulation of bioactive sphingolipid mediators in inflammation.

Authors:  Ashley J Snider; K Alexa Orr Gandy; Lina M Obeid
Journal:  Biochimie       Date:  2010-02-13       Impact factor: 4.079

8.  A functional role for CCR6 on proallergic T cells in the gastrointestinal tract.

Authors:  Ana Belén Blázquez; Adina Kay Knight; Hoheteberhan Getachew; Jonathan S Bromberg; Sergio A Lira; Lloyd Mayer; M Cecilia Berin
Journal:  Gastroenterology       Date:  2009-09-23       Impact factor: 22.682

9.  Tumour necrosis factor-alpha but not lipopolysaccharide enhances preference of murine dendritic cells for Th2 differentiation.

Authors:  Kazuhiro Kikuchi; Yoshiki Yanagawa; Toshimasa Aranami; Chikako Iwabuchi; Kazuya Iwabuchi; Kazunori Onoé
Journal:  Immunology       Date:  2003-01       Impact factor: 7.397

10.  FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology.

Authors:  Kunitomo Adachi; Kenji Chiba
Journal:  Perspect Medicin Chem       Date:  2007-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.